Neurocrine Biosciences Aktie
105,65
EUR
+2,70
EUR
+2,62
%
113,98
USD
-0,45
USD
-0,39
%
Werbung
Neurocrine Biosciences Aktie Analyse
14.10.05 | Neurocrine Biosciences overweight | Prudential Financial | |
08.09.05 | Neurocrine Biosciences outperform | Piper Jaffray | |
04.08.05 | Neurocrine Biosciences outperform | Piper Jaffray | |
25.07.05 | Neurocrine Biosciences outperform | Piper Jaffray | |
21.07.05 | Neurocrine Biosciences buy | UBS | |
20.07.05 | Neurocrine Biosciences Buy | UBS | |
18.07.05 | Neurocrine Biosciences outperform | Thomas Weisel Partners | |
18.07.05 | Neurocrine Biosciences Outperform | Thomas Weisel Partners | |
Werbung
|
|||
14.02.05 | Neurocrine Biosciences Overweight | Lehman Brothers |
Werbung
Werbung